×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NBIX – neurocrine biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NBIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
11:10 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
12/20
08:00 am
nbix
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Low
Report
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
12/16
10:03 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
12/16
09:17 am
nbix
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential [Yahoo! Finance]
Low
Report
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential [Yahoo! Finance]
12/16
08:30 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
12/16
08:06 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Medium
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
12/13
07:01 pm
nbix
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia [Yahoo! Finance]
12/13
06:55 pm
nbix
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Low
Report
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:00 am
nbix
neurocrine biosciences, inc.
BEAT
Report
3.6%
neurocrine biosciences, inc.
8/1/2024
07:00 am
nbix
neurocrine biosciences, inc.
BEAT
Report
6.0%
neurocrine biosciences, inc.
5/1/2024
07:00 am
nbix
neurocrine biosciences, inc.
BEAT
Report
0.7%
neurocrine biosciences, inc.
2/7/2024
07:00 am
nbix
neurocrine biosciences, inc.
BEAT
Report
-6.1%
neurocrine biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
08:07 am
nbix
Form 8-K NEUROCRINE BIOSCIENCES For: Dec 20
Low
Report
Form 8-K NEUROCRINE BIOSCIENCES For: Dec 20
12/19
04:47 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: ROBERTS EIRY
Medium
Report
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: ROBERTS EIRY
12/19
04:38 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: Delaet Ingrid
Medium
Report
Form 4 NEUROCRINE BIOSCIENCES For: Dec 17 Filed by: Delaet Ingrid
12/17
04:29 pm
nbix
Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid
Low
Report
Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid
12/3
06:53 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 29 Filed by: Onyia Jude
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 29 Filed by: Onyia Jude
11/29
01:41 pm
nbix
Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude
Neutral
Report
Form 144 NEUROCRINE BIOSCIENCES Filed by: Onyia Jude
11/12
05:59 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 08 Filed by: ROBERTS EIRY
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 08 Filed by: ROBERTS EIRY
11/7
07:43 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 04 Filed by: SHERWIN STEPHEN A
Medium
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 04 Filed by: SHERWIN STEPHEN A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/29
Q2/2019 6/30/2019 EPS 0.540 ZacksConsensus 0.270 ActVsEst 0.270 - Beat
10.3%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
TOP News Decliners
1/10
Form 4 NEUROCRINE BIOSCIENCES For: Jan 08 Filed by: ROBERTS EIRY
-8.1%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: